InVivoMAb Anti-HPV16 L2/Minor capsid protein L2 (Iv0014)

Catalog No.

VVV20801

Species reactivity

Human papillomavirus type 16

Host species

Human

Isotype

IgG1, kappa

Clonality

Monoclonal

Target

Minor capsid protein L2, L2

Concentration

3.2 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P03107

Applications

ELISA, Neutralization, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

Iv0014

Immunoinformatics approach for design novel multi-epitope prophylactic and therapeutic vaccine based on capsid proteins L1 and L2 and oncoproteins E6 and E7 of human papillomavirus 16 and human papillomavirus 18 against cervical cancer., PMID:39039819

Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development., PMID:36263027

A respirable HPV-L2 dry-powder vaccine with GLA as amphiphilic lubricant and immune-adjuvant., PMID:34740725

Computational Modeling of Immune Response Triggering Immunogenic Peptide Vaccine Against the Human Papillomaviruses to Induce Immunity Against Cervical Cancer., PMID:33973819

Recombinant Viral Capsid Protein L2 (rVL2) of HPV 16 Suppresses Cell Proliferation and Glucose Metabolism via ITGB7/C/EBPβ Signaling Pathway in Cervical Cancer Cell Lines., PMID:31819523

Production and Preliminary In Vivo Evaluations of a Novel in silico-designed L2-based Potential HPV Vaccine., PMID:31729940

In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine., PMID:31645650

Human Papillomavirus 16 Capsids Mediate Nuclear Entry during Infection., PMID:31092566

Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV)., PMID:28056100

Characterization of serum antibodies from women immunized with Gardasil: A study of HPV-18 infection of primary human keratinocytes., PMID:27113165

HPV16 L2 improves HPV16 L1 gene delivery as an important approach for vaccine design against cervical cancer., PMID:26925750

A Live Vector Expressing HPV16 L1 Generates an Adjuvant-Induced Antibody Response In-vivo., PMID:26855722

Robust In Vitro and In Vivo Neutralization against Multiple High-Risk HPV Types Induced by a Thermostable Thioredoxin-L2 Vaccine., PMID:26170394

A three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against oncogenic human papillomaviruses., PMID:24662712

Control of HPV infection and related cancer through vaccination., PMID:24008298

Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses., PMID:23752042

Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation., PMID:23536912

A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies., PMID:22593236

Influence of physiologic folate deficiency on human papillomavirus type 16 (HPV16)-harboring human keratinocytes in vitro and in vivo., PMID:22351779

The high risk HPV16 L2 minor capsid protein has multiple transport signals that mediate its nucleocytoplasmic traffic., PMID:22154072

Identification of the dynein light chains required for human papillomavirus infection., PMID:21166973

In vivo mechanisms of vaccine-induced protection against HPV infection., PMID:20833377

The RNA stability regulator HuR regulates L1 protein expression in vivo in differentiating cervical epithelial cells., PMID:18986664

Human papillomavirus type 16 E2 protein transcriptionally activates the promoter of a key cellular splicing factor, SF2/ASF., PMID:18945764

[Construction of codon-optimized HPV16 capsid genes in the eukaryotic co-expression vector and transfection of cells]., PMID:18616906

Human papillomavirus-like particles mediate functional delivery of plasmid DNA to antigen presenting cells in vivo., PMID:17293010

Human papillomavirus 16 minor capsid protein L2 helps capsomeres assemble independently of intercapsomeric disulfide bonding., PMID:16175337

Interaction of human papillomavirus type 16 L2 with cellular proteins: identification of novel nuclear body-associated proteins., PMID:12482659

Infectious virions produced from a human papillomavirus type 18/16 genomic DNA chimera., PMID:11967289

L1 interaction domains of papillomavirus l2 necessary for viral genome encapsidation., PMID:11287582

Translational inhibition in vitro of human papillomavirus type 16 L2 mRNA mediated through interaction with heterogenous ribonucleoprotein K and poly(rC)-binding proteins 1 and 2., PMID:9712894

Human papillomavirus type 16 and 18 gene expression in cervical neoplasias., PMID:1310950

Document Download

InVivoMAb Anti-HPV16 L2/Minor capsid protein L2 (Iv0014).pdf